Table 3

Treatment-related adverse events with all grades occurring in ≥5% of all patients

EventsPatients (N=156)
All gradesGrade ≥3
RCEP140 (89.7)3 (1.9)
Anemia43 (27.6)5 (3.2)
Hypothyroidism38 (24.4)0
Aspartate aminotransferase increased37 (23.7)2 (1.3)
Fever34 (21.8)0
Alanine aminotransferase increased27 (17.3)3 (1.9)
Asthenia27 (17.3)0
Cough27 (17.3)0
Pruritus22 (14.1)0
Blood thyroid-stimulating hormone increased21 (13.5)0
White blood cell count decreased19 (12.2)1 (0.6)
Proteinuria18 (11.5)0
Hypoalbuminemia15 (9.6)0
Productive cough13 (8.3)0
Thyroxine-free decreased13 (8.3)0
Rash12 (7.7)1 (0.6)
Blood creatinine increased12 (7.7)0
Gamma-glutamyltransferase increased10 (6.4)5 (3.2)
Neutrophil count decreased10 (6.4)0
Blood alkaline phosphatase increased8 (5.1)2 (1.3)
Occult blood positive8 (5.1)0
Decreased appetite8 (5.1)0
  • Data presented as n (%).

  • RCEP, reactive capillary endothelial proliferation.